Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 2/20 | 0.66 |
| ▸ | CES1 | P23141 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | RBBP9 | O75884 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2806946 | 0.91 | PLA2G4A (0.56) | PLA2G4ACES1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL6177200 | 0.87 | PLA2G4A (0.53) | PLA2G4ACES1NPC1RAB9ALMNA | |
| SCHEMBL17371667 | 0.84 | PLA2G4A (0.56) | PLA2G4ACES1SMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL1953501 | 0.80 | PLA2G4A (1.00) | PLA2G4ACES1MAPT | |
| SCHEMBL2161939 | 0.79 | CES1 (1.00) | PLA2G4ACES1MAPT | |
| Trifluoroacetic Acid SCHEMBL7448775 | 0.78 | PLA2G4A (0.44) | PLA2G4ACES1ALDH1A1 | |
| SCHEMBL20196298 | 0.78 | PLA2G4A (0.49) | PLA2G4ACES1SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL9346822 | 0.78 | PLA2G4A (0.49) | PLA2G4ACES1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL21598785 | 0.77 | ALDH1A1 (0.47) | PLA2G4ACES1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL15921297 | 0.77 | PLA2G4A (0.60) | PLA2G4ACES1SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040006126-A1 | Etoposide analogs and methods of use thereof | NIH-DEITR | 2004-01-08 | — | — | US | claimed |
| US-6566393-B1 | For therapy of cancer | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2003-05-20 | — | — | US | claimed |
| US-11918656-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2024-03-05 | — | — | US | disclosed |
| US-11661457-B2 | IGF-1R antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2023-05-30 | — | — | US | disclosed |
| US-20230002316-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2023-01-05 | — | — | US | disclosed |
| US-20230002316-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2023-01-05 | — | — | US | disclosed |
| EP-3607996-B1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PF MEDICAMENT (FR) | 2023-01-04 | — | — | EP | disclosed |
| EP-3607996-B1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PF MEDICAMENT (FR) | 2023-01-04 | — | — | EP | disclosed |
| US-11517625-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2022-12-06 | — | — | US | disclosed |
| US-11517625-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2022-12-06 | — | — | US | disclosed |
| US-20220105195-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2022-04-07 | — | — | US | disclosed |
| EP-1244678-A1 | PHOSPHONIC ACID DERIVATIVES AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE 1B (PTP-1B) | MERCK FROSST CANADA INC. (CA) | 2002-10-02 | — | — | EP | disclosed |
| US-20020058644-A1 | Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B) | MERCK FROSST CANADA LTD. (CA) | 2002-05-16 | — | — | US | disclosed |
| WO-2001046206-A1 | PHOSPHONIC ACID DERIVATIVES AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE 1B (PTP-1B) | MERCK FROSST CANADA & CO. (CA) | 2001-06-28 | — | — | WO | disclosed |
| EP-1067926-A2 | IMMUNOSUPPRESSIVE IMIDAZOLE DERIVATIVES AND THEIR COMBINATION PREPARATIONS WITH TACROLIMUS OR CYCLOSPORINS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-01-17 | — | — | EP | disclosed |
| US-6020495-A | Stereoselective method for synthesizing dolaphenine | PHARM-ECO LABORATORIES, INC. (US) | 2000-02-01 | — | — | US | disclosed |
| WO-1999051215-A2 | IMMUNOSUPPRESSIVE IMIDAZOLE DERIVATIVES AND THEIR COMBINATION PREPARATIONS WITH TACROLIMUS OR CYCLOSPORINS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-14 | — | — | WO | disclosed |
| EP-0846107-A1 | STEREOSELECTIVE METHOD FOR SYNTHESIZING DOLAPHENINE | Pharmeco Laboratories, Inc. (US) | 1998-06-10 | — | — | EP | disclosed |
| US-5750713-A | Stereoselective method for synthesizing dolaphenine | PHARM-ECO LABORATORIES, INC. (US) | 1998-05-12 | — | — | US | disclosed |
| WO-1996039399-A1 | STEREOSELECTIVE METHOD FOR SYNTHESIZING DOLAPHENINE | PHARM-ECO LABORATORIES, INC. (US) | 1996-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058644-A1 | Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B) | PPM1B, PTPRO, PTPA | PLA2G4A 801/4885CES1 239/4885SMN1; SMN2 4373/4885 |
| US-11517625-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | DDOST, DAD1, KRTCAP2 | PLA2G4A 1319/4885CES1 820/4885SMN1; SMN2 4439/4885 |
| US-20230002316-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | NR1H4, HCAR3, VDR | PLA2G4A 1800/4885CES1 712/4885SMN1; SMN2 4753/4885 |
| US-11918656-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | DDOST, DAD1, KRTCAP2 | PLA2G4A 1319/4885CES1 820/4885SMN1; SMN2 4439/4885 |
| US-11661457-B2 | IGF-1R antibody-drug-conjugate and its use for the treatment of cancer | IGF1R, IGFBP1, IGFBP5 | PLA2G4A 2651/4885CES1 1981/4885SMN1; SMN2 3883/4885 |
| US-20040006126-A1 | Etoposide analogs and methods of use thereof | LPXN, TET2, TH | PLA2G4A 2807/4885CES1 3398/4885SMN1; SMN2 3448/4885 |
| US-20220105195-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | KRTCAP2, DDOST, DAD1 | PLA2G4A 1367/4885CES1 993/4885SMN1; SMN2 4595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.